GI Cancer ESMO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / gi-cancer-esmo-2024-highlights

Rahul Gosain, MD; Rohit Gosain, MD; and Kristen Ciombor, MD, discuss recent clinical trial results from ESMO 2024, including LEAP-012 in lung cancer, KEYNOTE-811 in gastric cancer, POD1UM-303/InterAACT2 in anal cancer, and NICHE-2 in colorectal cancer, highlighting advancements in immunotherapy and targeted treatments across multiple tumor types.

3 KOLs are featured in this series.

EP. 1: ESMO 2024: Updates on LEAP-012

Rahul Gosain, MD;Rohit Gosain, MD;Kristen Ciombor, MD
October 10th 2024

Panelists discuss how LEAP-012 trial results show promising progression-free survival, while anticipating further data on overall survival outcomes.

3 KOLs are featured in this series.

EP. 2: KEYNOTE-811: Latest Updates From ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Kristen Ciombor, MD
October 10th 2024

Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.

3 KOLs are featured in this series.

EP. 3: Key Highlights on POD1UM-303 Presented at ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Kristen Ciombor, MD
October 10th 2024

Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.

3 KOLs are featured in this series.

EP. 4: ESMO 2024: Key Updates From NICHE-2

Rahul Gosain, MD;Rohit Gosain, MD;Kristen Ciombor, MD
October 10th 2024

Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.